etanercept biosimilars
Selected indexed studies
- Etanercept biosimilars. (Rheumatol Int, 2015) [PMID:24980068]
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. (Ann Rheum Dis, 2023) [PMID:36357155]
- Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. (J Am Acad Dermatol, 2019) [PMID:30772098]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Etanercept biosimilar SB-4. (2019) pubmed
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. (2023) pubmed
- Biosimilars in rheumatology. (2019) pubmed
- Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. (2019) pubmed
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. (2020) pubmed
- Etanercept biosimilars. (2015) pubmed
- Efficacy, safety and immunogenicity of etanercept biosimilars versus reference biologics in patients with rheumatoid arthritis: A meta-analysis. (2023) pubmed
- Past, Present and (Foreseeable) Future of Biological Anti-TNF Alpha Therapy. (2023) pubmed
- Efficacy, safety, and immunogenicity of biosimilars compared with the biologic etanercept in patients with rheumatoid arthritis: a systematic review and meta-analysis. (2024) pubmed
- [Immunogenicity of biosimilars]. (2016) pubmed